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ABSTRACT  
The enhanced cardiovascular disease (CVD) risk experienced by patients with 
rheumatoid arthritis (RA) remains largely unexplained.  Traditional risk factors 
including hypertension, dyslipidemia, diabetes, smoking and altered adiposity states 
do not fully account for the increased CVD risk in RA.  High grade systemic 
inflammation, as characteristically present in patients with RA, is associated with 
adverse metabolic risk factor profiles and can directly increase atherogenesis.  
Further, genetic polymorphisms are related to CVD in RA.  Notably, the impact of 
cardiovascular risk factors on CVD is epidemiological health transition stage 
dependent within populations.  Indeed, cardiovascular risk factor-CVD relations 
consistently differ amongst patients with RA from developed compared to developing 
populations.  In line with these findings, adequate CVD risk stratification in RA 
currently eludes us.    
Adipose tissue derived adipokines are major determinants of systemic metabolism.  
Several recent studies revealed that adipokines are involved in RA activity and 
severity.  Adipokines play key roles in interactions between obesity, metabolic 
cardiovascular risk factors and systemic inflammation, all of which contribute to 
cardiovascular pathology.  These adipokine effects depend on pathophysiological 
context.  Against this background, in the present study, we investigated the 
associations of omentin concentrations with subclinical CVD and whether population 
origin and RA activity and severity impacts on the respective relationships.   
Omentin concentrations were measured in 213 (104 black; 109 white) RA patients. 
Relationships of omentin levels with those of 6 endothelial activation markers, 
ultrasound determined carotid intima-media thickness and plaque, and matrix 
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metalloproteinase (MMP)-2, -3 and -9 that mediate plaque stability, were identified in 
multivariate regression models. 
Omentin concentrations were inversely associated with MMP-3 levels (β=-364 
(0.113), p=0.002).  This relationship was influenced by population origin, RA activity 
and the erythrocyte sedimentation rate (ESR) and joint deformity count (interaction p 
value=0.009, 0.04, 0.04 and 0.007, respectively).  Accordingly, in stratified analysis, 
the omentin-MMP-3 concentration relationship was reproduced in white (β (SE)=- 
0.450 (0.153), p=0.0004) but not black patients (β (SE)=- 0.099 (0.195), p=0.6), in 
participants with disease remission or mild disease activity (β (SE)=-0.411 (0.139), 
p=0.004) but not with moderate or severe RA activity (β (SE)=-0.286 (0.202), p=0.2), 
and in those with a small (β (SE)=-0.534 (0.161), p=0.001) but not large erythrocyte 
sedimentation rate (ESR) (-0.212 (0.168), p=0.2) and without  (β (SE)=-0.554 
(0.165), p=0.0001) but not with large joint deformity counts (-0.110 (0.173), p=0.5). 
Omentin levels were unrelated to endothelial activation and atherosclerosis. 
Omentin concentrations do not represent endothelial activation and atherosclerosis 
extent in RA. However, omentin concentrations were inversely associated with those 
of MMP-3, a surrogate marker of plaque vulnerability to rupture, in white but not 
black Africans with RA.  This inverse relationship was also absent RA patients with 
moderate or severe RA activity and large ESR values and joint deformity counts.  A 
loss of beneficial effects of omentin on plaque instability may contribute to the link 
between severe disease and increased cardiovascular risk in RA.                                                                                                                                                   
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1.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a prototypic chronic inflammatory condition that affects 
0.5 to 1 % of the population.  The core characteristic of RA is synovitis that results in 
the destruction of cartilage and bone. In addition to synovial inflammation and 
hyperplasia, rheumatoid arthritis is characterised by autoantibody production (anti-
citrullinated protein antibody [ACPA]) and rheumatoid factor) with systemic 
inflammation resulting in additional complications compromising multiple organ 
systems (McInnes & Schett, 2011).  In the presence of extraarticular manifestations 
and comorbidities, this autoimmune disease is characterised by substantial disability 
as well as an increase in patient mortality (Alamanos & Drosos, 2004).  
 
RA comprise several disease subsets with disease manifestations that involve 
disparate inflammatory cascades (Scott et al., 2010; Van der Helm-van Mil & 
Huizinga, 2008).  One such cascade comprises the overproduction and 
overexpression of tumor necrosis factor (TNF) (Feldman et al., 1996; Scott et al., 
2010) eliciting a response from additional cytokines such as interleukin-6 (IL-6). 
Overproduction of inflammatory cytokines is stimulated by abnormal activity of 
synovial cells or synoviocytes within the joints of RA patients. A role of osteoclast 
activation in joint destruction has also been suggested (Cohen et al., 2008). 
 
Although the exact etiology is unknown, RA comprises complex interactions between 
genetic- and environmental factors (Scott et al., 2010; McInnes & Schett, 2011; 
Gibofsky et al., 1978). Twin studies yielding concordance rates of 15-30 % in 
monozygotic twins and 5 % in dizygotic twins (Silman & Pearson, 2002), suggest 
that RA prevalence can be attributed to genetic factors (McInnes & Schett, 2011; 
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Gibofsky 2012).   In addition to twin studies, the shared epitope hypothesis suggests 
the impact of class II molecules in the pathogenesis of rheumatoid arthritis. The 
human leukocyte antigen (HLA)-DRB1 locus confers disease susceptibility in 
patients who test positive for rheumatoid factor and/or ACPA (Gregersen et al., 
1987; Mc Innes & Schett, 2011; Gibofsky 2012). Gene interactions between (HLA)-
DRB1 and PTPN22 have been described thereby adding to the complexity of the 
exact etiology in rheumatoid patients (Karlberg et al., 2007).  With regards to gene-
environment interactions, smoking confers increased risk for rheumatoid arthritis in 
patients presenting (HLA)-DR4 alleles (Symmons et al., 1997). Synergistically, 
smoking confers increased risk for ACPA-positive disease in the presence of (HLA)-
DRB1 alleles (McInnes & Schett, 2011; Klareskog et al., 2006).    
 
Infectious agents triggering the initiation and formation of immune complexes have 
also been shown to associate with RA (Auger & Roudier, 1997; Kamphuis et al., 
2005). Infectious agents implicated in the pathogenesis of rheumatoid arthritis 
include Epstein-Barr virus, cytomegalovirus, parvo- and rubella virus (Alamanos & 
Drosos, 2004).  
 
In addition to the above, most RA patients are women.  Studies suggest an 
increased incidence of rheumatoid arthritis in women with their susceptibility being 
increased in the presence of oral contraceptives and reduced with parity (Silman & 
Pearson 2002, Alamanos & Drosos, 2004, Gibofsky, 2012).  
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1.2 CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS 
 
Where cardiovascular disease (CVD) accounted for less than 10 % of global 
mortality at the beginning of the 20th century, it is now estimated that 30 % of global 
deaths are attributable to diseases of the cardiovascular system (Gaziano, 2005).  
Almost 80 % of the CVD burden occurs in developing countries (Yusuf et al., 2004).  
It is well established that RA confers increased risk for cardiovascular disease 
including ischemic heart disease and cerebrovascular accidents (Avina-Zubieta et 
al., 2008; Gonzalez-Gay et al., 2005; Dessein et al., 2007; Gonzalez-Gay et al., 
2007; Rodriguez-Rodriguez et al., 2012).  A meta-analysis by Avina-Zubieta et al 
(2008) concludes that the CVD mortality rate is increased by as much as 50 % in RA 
patients as compared to that in the general population.  
Genetic determinants contribute to the increased risk of CVD and mortality 
experienced by RA (Gonzalez-Gay et al, 2007).  Additionally, high grade 
inflammation and the impact of inflammatory changes on traditional risk factors is 
most pertinent in the present context (Dessein et al., 2007).  The development of 
accelerated atherosclerosis in response to chronic inflammatory responses 
contributes to the increased CVD risk observed in patients with rheumatoid arthritis 
(Gonzalez-Gay et al., 2005; Gonzalez-Gay et al., 2007).  Although traditional risk 
factors including dyslipidaemia, hypertension, smoking and diabetes have repeatedly 
been shown to predict cardiovascular events in a general population (Menotti et al., 
2009; Yusuf et al., 2004, Yusuf et al., 2001b; O’Donnell et al., 2010), these 
conventional risk factors do not fully account for the adverse outcomes in patients 
with RA (del Rincon, 2001).  In this regard, alternative CVD risk profiling strategies 
need to be evaluated in specific RA populations.  This requires consideration of 
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differences in epidemiological disease health transition stages amongst persons 
living in developed countries and developing countries, an issue that is particularly 
relevant to African populations.   
Solomon et al. recently reviewed findings on cardiovascular risk factors and 
subclinical CVD in black African patients with RA from a developing population.  
Despite marked RA activity and increased severity observed in this group (Solomon 
et al., 2005) less frequent atherosclerotic CVD has been reported in this population 
at large.  Dessein et al. (2013e) investigated cardiovascular risk factor profiles and 
their associations with carotid atherosclerotic changes in black Africans with RA.  
Despite a higher prevalence of hypertension and diabetes, both conventional and 
non-conventional CVD risk burdens as well as arterial stiffness were found to be 
similar in black compared to white Africans (Solomon et al., 2010; Dessein et al., 
2013b).  Unexpectedly, a similar atherosclerosis burden was noted in black 
compared to white African RA patients (Solomon et al., 2012).  Traditional and non-
traditional risk factors were independently related to atherosclerosis in white but not 
black African RA patients.  In contrast to these findings, the Arthritis Impact 
Measurement Scales tension score and non-steroidal anti-inflammatory agent use 
were associated with atherosclerosis in black Africans only.  Additional studies by 
the same group found that black African women with RA had a 6.1 fold increased 
metabolic syndrome (MetS) prevalence compared to whites (Solomon A et al., 2011; 
Dessein et al., 2013b).  In this regard, MetS triglycerides and the number of MetS 
criteria associated independently with plaque in white but, again, not in black African 
patients with RA.  Also, excess adiposity was independently related to enhanced 
atherosclerosis in white by not black African women with RA (Solomon et al., 2012).         
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A reduced estimated glomerular filtration rate (eGFR) confers increased risk for 
adverse cardiovascular events (Salles et al., 2011).  In the above mentioned cohort, 
a reduced eGFR was present in 49.1 and 30.6% of black and white Africans, 
respectively (Dessein et al., 2015).  Moreover, upon employing receiver operator 
characteristic curve analysis, 7 of 8 assessed eGFR equations predicted the 
presence of carotid plaque with sensitivities and specificities ranging from 42 to 60% 
and 70 to 91%, respectively, in black African RA patients.  EGFR equations did 
however not accurately predict prevalent atherosclerosis amongst white Africans 
with RA.  It is well recognized that the presence of carotid plaque confers increased 
CVD risk.                                                                                                                      
These findings are significant for black African patients with RA: first, they should no 
longer be considered immune to atherosclerosis; second, atherogenesis may 
currently consist of a different process in these patients; third, traditional and non-
traditional cardiovascular risk factor evaluation as recommended in estimating the 
actual CVD risk in RA patients from developed populations should not be employed 
for the respective purpose in these patients; fourth, current optimal CVD risk 
stratification likely requires direct vascular imaging (e.g. carotid ultrasound) in order 
to determine CVD prevention by cardiovascular drugs, e.g. statins; fifth, the use of 
eGFR equations in CVD risk stratification is promising amongst black Africans who 
have no access to vascular imaging.    
RA increases CVD risk to a similar extent as diabetes (Solomon et al., 2010; 
Nurmohamed et al., 2010; Peters et al., 2010).  In addition to traditional 
cardiovascular risk factors, systemic inflammation is strongly implicated in the 
enhanced atherosclerosis burden and CVD event rates associated with RA. 
Traditional cardiovascular risk factor based risk equations including the Framingham 
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score underestimate the actual CVD risk in RA.  There is currently a need for 
alternative strategies in the elucidation of CVD risk and its optimal stratification in RA 
(Crownson & Gabriel, 2011; Dessein et al., 2013d).  It is against this background that 
the need for identifying novel biomarkers of cardiovascular risk in this inflammatory 
disease is imperative (Crownson & Gabriel, 2011; Dessein et al., 2013d). 
 
1.3 ADIPOKINES AS NOVEL BIOMARKERS 
The role of adipose tissue in systemic metabolism and as a mediator of inflammatory 
changes is no longer disputed (Ouchi et al., 2003; Berg & Scherer, 2005).  Indeed, 
the importance of white adipose tissue as an endocrine organ that secretes bioactive 
molecules including hormones and proteins, has been recognised (Di Raimo et al., 
2015).  White adipose tissue is predominantly present as subcutaneous and visceral 
adiposity comprising not only adipocytes but also pre-adipocytes, fibroblasts, 
vascular cells and immune cells (collectively referred to as stromal-vascular fraction 
(SVF) of adipose tissue) (Di Raimo et al, 2015). Protein secretion by adipocytes as 
well as SVF (adipose tissue), contributes to mechanisms of vascular insult and 
atheromatous changes (Ouchi et al., 2011; Berg & Scherer, 2005).  These soluble 
bioactive proteins that exhibit both pro- and anti-inflammatory effects, are referred to 
as adipo(cyto)kines (Scrivo et al., 2013; Funahashi et al., 1999).  Trayhurn & Wood 
(2004) however recommend the use of the abbreviated term adipokine as a more 
accurate depiction of protein functionality and origin.  Adipo(cyto)kine draws 
inference that the bioactive proteins secreted by adipose tissue are cytokines or 
cytokine-like which holds true in the case of IL-6 for instance but  not  for all of the 
adipokines (Trayhurn & Wood, 2004). 
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In the presence of obesity, hypertrophic adipocytes and stromal cells within the 
adipose tissue mediate systemic inflammatory changes that in turn effect a myriad of 
pathogenic pathways.  The immunological activity state of adipose tissue is altered in 
the presence of obesity as mediated through changes in cellular composition (Ouchi 
et al., 2012).  In addition to changes in cellular composition, the expression of 
adipokines varies depending on the site of adipose deposit (Samaras et al., 2010; 
Fried et al., 1998).  Circulating adipokine levels are thus representative of both the 
extent of adiposity as well as its biological activity (Dessein & Solomon, 2013).   
Numerous adipokines have been identified and investigated in the past few decades. 
Complement factor D or the serine protease Adipsin, was the first adipokine to be 
identified (Cook et al., 1987).  This was followed by the identification of TNF as pro-
inflammatory molecule that is secreted by adipose tissue and implicated in various 
inflammatory cascades in the presence of obesity (Ouchi et al., 2011; Hotamisligil et 
al., 1993). The current focus on adipose tissue as a bioactive endocrine organ was 
fuelled by the discovery of the cytokine-like hormone, leptin (Zhang et al., 1994; 
Trayhurn & Wood, 2004). The subsequent discovery of adiponectin 
(ACRP30/ADIPOQ) played a key role in understanding the pathophysiology of 
obesity-linked disease cascades (Hu et al., 1996; Maeda et al, 1996; Scherer et al., 
1995).  
In addition to TNF and IL-6, some of the most pertinent pro-inflammatory adipokines 
include leptin (Mantzoros CS, Farooqi et al., 2002; Santos-Alvares et al., 1999; Lord 
et al., 1998), resistin (Jamaluddin et al., 2012; Bokarewa et al., 2005; Verma et al., 
2003), Retinal binding protein-4 (RBP-4) (Kotnik et al., 2011; Kloting et al., 2007; 
Balagopal et al., 2007), chemerin (Yamawaki et al., 2011; Rourke et al., 2013; 
Dessein et al., 2014d) and visfatin (Revollo et al., 2007; Moschen et al., 2007). Anti-
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inflammatory adipokines include adiponectin and more recently identified SFRP5 
(Ouchi et al., 2010). 
These and other adipokines play a key roles in interactions between obesity,  
dyslipidemia, type 2 diabetes mellitus, hypertension and metabolic syndrome, all of 
which contribute to cardiovascular pathology (Berg & Scherer, 2005). Importantly in 
the present context, the involvement of adipokines in the pathophysiology of 
rheumatoid arthritis has been documented in numerous studies that alluded to both 
RA activity and severity (Gomez et al., 2011).   
Dessein et al evaluated the role of adipokines in a rheumatoid arthritis cohort within 
African context.  The mentioned studies found that adiponectin concentrations were 
reduced in black RA patients of African descent.  In these patients, adiponection 
concentrations were associated with favourable lipid concentrations and 
paradoxically with high blood pressure values (Dessein et al., 2013a). In white RA 
patients, adiponectin concentrations were also paradoxically associated with 
increased endothelial activation (Dessein et al., 2013e).  These findings allude to the 
fact that adiponectin might exhibit altered expression and effects in the presence of a 
prototypic inflammatory disease such as rheumatoid arthritis.  Varying 
concentrations of adiponectin in patients with RA could represent a compensatory 
mechanism proportional to CVD risk aimed at reducing this risk.  Regardless of race, 
adiponectin related to a decreased presence of carotid plaque in RA patients 
amongst those without but not with deformed joints (Dessein et al., 2013a). The 
absence of the suggested adiponectin induced CVD risk protection may thus 
contribute to the reported link between RA severity and enhanced CVD risk in RA.   
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The adipokine resistin was associated with inflammation, endothelial activation and 
atherosclerosis (Dessein et al., 2013c; Dessein et al., 2014c).   
In the presence of obesity, endothelial activation was mediated by leptin in young RA 
patients in the presence of obesity (Dessein et al., 2014a). Dessein et al. employed 
sequential multivariate models, which revealed that obesity and chronic kidney 
disease induced atherosclerosis was mediated by leptin in RA.  
Chemerin associated with angiopoietin 2 concentrations, which contribute to 
advanced atherosclerosis.  Excess adiposity influenced the chemerin-atherosclerotic 
phenotype relations in RA (Dessein et al., 2014d).   
The pro-inflammatory adipokine RBP-4 was paradoxically associated with reduced 
endothelial activation but related to increased plaque prevalence in black and obese 
patients with RA (Dessein et al., 2014b).  
The significance of these findings suggest that (1) adipokines contribute to RA 
related increased CVD risk; (2) adipokine concentrations comprise promising 
markers in CVD risk stratification in RA independent of traditional risk factors and 
disease activity; (3) targeting adipokines to treat RA can impact CVD risk; (4) data on 
adipokine production and adipokine-CVD relations can be RA specific; (5) the impact 
of adipokines on CVD risk in RA is pathophysiological context dependent, which 
calls for sensitivity analysis; (6) population origin impacts on adipokine-CVD 
relations.     
Within the above context and in addition to the mentioned adipokines, Dessein et al 
further examined the impact of conventional compared to nonconventional 
cardiovascular risk factors including interleukin-6 levels on endothelial activation 
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patients with RA (Dessein et al., 2013a).  Of the cardiovascular risk factors 
investigated, IL-6 contributed substantially to endothelial activation as estimated by 
an SD (z) score of endothelial activation molecule concentrations.  This relationship 
was reproduced in various subgroups suggesting that the adipokine IL-6 can be 
employed in cardiovascular risk stratification in RA. 
Taken together, reported evidence indicates that adipokines indeed mediate 
interactions amongst adiposity, systemic inflammation, RA activity and severity as 
well as CVD severity.  This calls for the elucidation of more novel adipokines in the 
pathophysiology and enhanced CVD risk and its stratification associated with RA.   
 
1.4  OMENTIN                                                                                                      
The adipokine omentin, has recently received considerable attention as a critical 
mediator of metabolic and cardiovascular homeostasis. Omentin-1 (Intelectin-1, 
endothelial lectin HL-1, intestinal lactoferrin receptor, galactofuranose-binding lectin) 
was initially identified in small intestinal Paneth cells in 1998 (Komiya et al., 1998).  
Omentin was implicated in pathogen recognition and gut defensive mechanisms 
against pathogenic bacterial translocation (Komiya et al., 1998; Shaffler et al., 2005). 
This anti-inflammatory adipokine is predominantly expressed by the SVF of adipose 
tissue.  Although omentin is produced in visceral rather than subcutaneous adipose 
tissue, in vitro studies suggest that omentin-1 exhibits insulin-sensitising effects in 
both visceral and subcutaneous adipose tissue.  This is mediated through Akt/PKB 
phosphorylation in the absence of insulin (Yang et al., 2006). 
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Most reported evidence indicates that omentin protects against cardiometabolic risk 
(Tan et al., 2010).  As applies to adiponectin that was discussed earlier as anti-
inflammatory and protective adipokine, omentin production is decreased in obesity 
(De Souza et al., 2007).  Reduced omentin concentrations are associated with 
metabolic risk factors including impaired glucose metabolism, low HDL-cholesterol 
levels and hypertension (Pan et al., 2010; Moreno-Navarrete et al., 2010; Saremi et 
al., 2010; Shibata et al., 2012).  Omentin induces vasodilation through endothelial-
derived nitric oxide production (Yamawaki et al., 2010), and decreases tumor 
necrosis factor-α induced endothelial activation (Zhong et al., 2012).  Reduced 
omentin concentrations are associated with arterial stiffness (Yoo et al., 2011), 
atherosclerosis (Shibata et al., 2011; Liu et al., 2011; Kadoglou et al., 2014), plaque 
vulnerability (Kadoglou et al., 2014; De Jager et al., 2016), established coronary 
artery disease presence and severity (Shang et al., 2011; Zhong et al., 2011; 
Shibata  et al., 2011), diastolic dysfunction (Greulich et al., 2013) and, disease 
severity and incident cardiovascular event rates amongst patients with heart failure 
(Namuri et al., 2014).  
As previously alluded to, concentrations of adipokines other than omentin are related 
to inflammation, traditional cardiovascular risk factors and subclinical CVD in RA 
(Gonzalez-Gay et al., 2008; Gonzalez-Gay et al., 2009; Dessein et al., 2013a; 
Dessein et al., 2013c; Dessein et al., 2013e; Dessein et al., 2014a; Dessein et al., 
2014b; Dessein et al., 2014c; Dessein et al., 2014d; Dessein et al., 2014e; Popa et 
al., 2009; Rourke et al., 2013 ).  Cellular studies revealed that several adipokines 
participate in the pathophysiology of RA (Gomez et al., 2011; Eisinger et al., 2012).  
Synovial fluid levels of omentin were reduced in RA compared to osteoarthritis 
patients (Senolt et al., 2010).  Reduced expression of omentin in omental adipose 
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tissue may contribute to transmural intestinal inflammation in Crohn’s disease 
(Shaffler et al., 2005).  Omentin decreases vascular inflammation (Yamawaki et al., 
2011).  These findings suggest that omentin has anti-inflammatory properties 
(Lemieux et al., 2001).  Whether omentin can contribute to the enhanced CVD risk 
and its stratification in RA awaits investigation. 
 
1.5 STUDY OBJECTIVES 
In the present study, we therefore explored the independent relationships of omentin 
concentrations with metabolic risk factors, endothelial activation, atherosclerosis and 
matrix metalloproteinases (MMP) 2, 3 and 9 that mediate altered plaque vulnerability 
to rupture (Back et al., 2010; Galis et al., 1994; Beaudeux et al., 2003; Samnegard et 
al., 2006; Wu et al., 2005; Schoenhagen et al., 2002; Inoue et al., 2003), in patients 
with RA.  We also determined the potential influence of population origin, disease 
activity and severity and systemic inflammation on the respective relations.  
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MATERIALS AND METHODS 
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2.1  PATIENTS 
This study was performed according to the principles outlined in the Helsinki 
declaration and was approved by the Human Research Ethics Committee (Medical) 
(approval number: M12-05-62 ) from the University of the Witwatersrand, 
Johannesburg, South Africa, and forms part of an ongoing investigation on 
cardiovascular risk in RA patients from a public and private health care center 
(Dessein et al., 2013a; Dessein et al., 2013c; Dessein et al., 2013e ;Dessein et al., 
2014a; Dessein et al., 2014b; Dessein et al., 2014c; Dessein et al., 2014d; Dessein 
et al., 2014e). A total of 213 (104 black, 109 white) patients that met the 1988 
American College of Rheumatology (ACR) and 2012 ACR/European League Against 
Rheumatism criteria for RA participated (Arnett et al., 1988; Aletaha et al., 2010). 
Informed, written consent was obtained from all participants. 
 
2.2  ASSESSMENTS 
Baseline characteristics and conventional metabolic risk factors were recorded using 
previously described methods (Dessein et al., 2013a; Dessein et al., 2013c; Dessein 
et al., 2013e ;Dessein et al., 2014a; Dessein et al., 2014b; Dessein et al., 2014c; 
Dessein et al., 2014d; Dessein et al., 2014e). Briefly, demographic features and 
anthropometric measures including height, weight, waist and hip circumference were 
recorded according to standard protocols.  Body mass index (BMI) and waist 
circumference were used as indicators of generalized adiposity and fat distribution, 
respectively.  RA activity was evaluated by the Clinical Disease Activity Score 
(CDAI).  Disease severity markers included the number of deformed joints, 
rheumatoid factor (RF) status and current or previously recorded (hospital record 
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review) extra-articular manifestations that were defined as the presence of 
pericarditis, pleuritis, Felty’s syndrome, cutaneous vasculitis, neuropathy, scleritis or 
episcleritis, retinal vasculitis, glomerulonephritis, vasculitis affecting other organs, 
amyloidosis, keratoconjunctivitis, xerostomia, Sjorgen’s syndrome, pulmonary 
fibrosis, bronchiolitis obliterans organizing pneumonia, cervical myelopathy, 
subcutaneous nodules and rheumatoid nodules in other locations.  C-reactive protein 
(CRP) concentrations were evaluated by immunoturbidimetric methods. We 
measured IL-6 concentrations using a solid-phase sandwich enzyme-linked 
immunosorbant assay (ELISA) (Quantikine HS, R&D Systems, Inc., Minneapolis, 
MN, USA). The lower detection limit ranged from 0.02 to 0.11 pg/mL and the inter- 
and intra-assay coefficients of variation were 7.8 and 7.4%, respectively. Standard 
laboratory tests of erythrocyte sedimentation rate, renal and liver function, 
hematological variables, lipids and glucose were performed. The glomerular filtration 
rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (Dessein et al., 2015). Use of synthetic disease 
modifying agents and cardiovascular drugs were recorded. 
Evaluated conventional metabolic risk factors comprised systolic and diastolic blood 
pressures, high-density lipoprotein, low-density lipoprotein and triglyceride 
concentrations and lipid ratios, as well as serum glucose levels. Hypertension was 
defined as an average systolic blood pressure ≥ 140 mmHg and/or diastolic blood 
pressure of ≥ 90 mmHg and/or current use of antihypertensive medications. Patients 
were diagnosed as having dyslipidemia when the cholesterol/HDL ratio was > 4 
(Peters et al., 2010). Participants were identified as diabetic when their fasting 
plasma glucose concentration was ≥ 7 mmol/l or when using glucose lowering 
agents.  
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The concentrations of six adipokines other than omentin 1 were also measured and  
included total and high molecular weight adiponectin, leptin, chemerin, retinol-
binding protein 4 (RBP-4) and resistin as previously described by us (Dessein et al., 
2013a; Dessein et al., 2013c; Dessein et al., 2013e ;Dessein et al., 2014a; Dessein 
et al., 2014b; Dessein et al., 2014c; Dessein et al., 2014d; Dessein et al., 2014e).  
Early endothelial activation molecule concentrations were assessed, including those 
of soluble E-selectin, vascular cell adhesion molecule 1 (VCAM-1), intercellular 
adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein 1 (MCP-1), using 
solid phase sandwich ELISA (QuantikineHS).  The lower detection limits were 0.009 
ng/l, 0.6 ng/l, 0.096 ng/l and 5.0 pg/ml, respectively; their interassay and intraassay 
coefficients of variation were 7.9 and 5.8, 7.0 and 3.1, 5.5 and 4.6, and 5.7 and 
5.8%, respectively.  Also, the levels of 2 further endothelial activation markers 
including asymmetric dimethylarginine (ADMA) and angiopioetin 2 were evaluated, 
with lower detection limits of 0.05 μmol/l and 1.2 pg/ml, respectively; their interassay 
and intraassay coefficients of variation were 7.8 and 8.8, and 8.9 and 5.9%, 
respectively. 
Carotid artery ultrasound (US) measurements were conducted by two operators.   
Images of at least 1cm length of the distal common carotid arteries were obtained for 
measurement of the carotid intima media thickness, using the optimal angle of 
incidence (defined as the longitudinal angle of approach where both branches of the 
internal and external carotid artery are clearly visible (Gepner et al., 2006). Carotid 
intima media thickness measurements were made with high-resolution B-mode US 
(Image Point, Hewlett Packard and SonoCalc IMT, Sonosite Inc.), using linear array 
7.5 MHz probes. The US methods utilized in the private sector have been previously 
published in detail (Dessein et al., 2007). The public sector equipment employed 
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specialized software allowing semi-automated border detection, which was 
previously found to provide highly reproducible results (Gepner et al., 2006). The c-
IMT measurement was recorded as the mean of the left and right carotid artery 
values. Carotid artery plaque was defined as a focal structure that encroaches into 
the arterial lumen of at least 0.5mm or 50% of the surrounding intima-media 
thickness value, or demonstrates a thickness of > 1.5 mm as measured from the 
media-adventitia to the intima-lumen interface (Touboul et al., 2007). Both research 
operators were blinded to patient cardiovascular risk profiles.  Repeat US 
examinations on 23 patients from either public or private sectors confirmed an 
intraobserver coefficient of variation of 5.8% and 4.1% for private and public 
healthcare patients, respectively, and an interobserver coefficient of variation of 
8.0% for measurements made by two operators.  Both operators identified carotid 
artery bulb and/or internal carotid artery plaque in 11 of these 23 patients, with full 
agreement.  
MMP-2, -3 and -9 concentrations were quantified.  Their lower detection limits were 
3.5 ng/ml, 0.3 pg/ml and 10 pg/ml, respectively; the interassay and intraassay 
coefficients of variation were 10.0 and 12.0% for each of the 3 measurements. 
Omentin-1 concentrations were determined by a solid-phase sandwich ELISA 
(QuantikineHS). The lower detection limit was 0.4 ng/ml.  
 
2.3 DATA MANAGEMENT AND ANALYSIS 
Continuous variables were expressed as mean (SD), or median (interquartile range) 
when non-normally distributed.  Non-normally distributed characteristics were also 
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logarithmically transformed prior to their inclusion in multivariable statistical analysis.  
Dichotomous variables were expressed as proportions or percentages.  
The relationship of age at disease onset, age at time of the study, gender and 
population grouping with omentin concentrations were determined in a mixed 
regression model.  Associations of other baseline characteristics with omentin levels 
were assessed in demographic characteristic adjusted models. 
The independent relationships of omentin levels with metabolic risk factors, 
endothelial activation molecule concentrations, atherosclerosis and MMP levels were 
evaluated in multivariate linear of logistic models with adjustment for potential 
confounders and/or mediators as identified in the previous analysis.   
Amongst patients with RA, it is those with severe disease that are particularly at high 
risk for CVD (Dessein et al., 2007; Solomon et al., 2010; Nurmohamed et al., 2010; 
Peters et al., 2010).  Further, adipokine effects on cardiovascular risk depend on 
pathophysiological context (Gonzalez-Gay et al., 2008; Gonzalez-Gay et al., 2009; 
Dessein et al., 2013a; Dessein et al., 2013c; Dessein et al., 2013e; Dessein et al., 
2014a; Dessein et al., 2014b; Dessein et al., 2014c; Dessein et al., 2014d; Dessein 
et al., 2014e; Popa et al., 2009; Rourke et al., 2013), which includes not only disease 
activity and severity as well as systemic inflammation but also adiposity status and 
population origin in RA patients (Dessein et al., 2013e; Dessein et al., 2014b).  We 
therefore assessed the impact of the respective patient characteristics on omentin 
concentration-subclinical CVD relations by adding the appropriate interaction terms 
and their individual components to the models, and subsequent stratified analysis, 
that is, in subgroups with and without patients characteristics of interest, when 
indicated (significant interaction p values).  For this purpose, patients with a BMI of ≥ 
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30 kg/m2 and those who met the National Cholesterol Education Program for 
metabolic syndrome (MetS) waist criterion (Dessein et al., 2006) were considered to 
sustain overall and abdominal obesity, respectively.  When appropriate, patients 
were categorized in subgroups based on median values. 
Statistical computations were made using IBM SPSS statistics (version 22.0, IBM, 
USA). Statistical significance was set as p < 0.05. 
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3.  RESULTS 
Descriptive statistics of recorded patient characteristics are detailed in Table 1. The 
mean (±SD) age at time of the study was 56.9 (11.1) years with a mean disease 
duration of 13.5 (9.5) years.  The median (interquartile range) CDAI was 7 (Solomon 
et al., 2010; Nurmohamed et al., 2010; Peters et al., 2010; Crowson & Gabriel, 2011; 
Dessein et al., 2013d; Komiya et al., 1998; Shaffler et al., 2005; Yang et al., 2006; 
Lemieux e, 2001; Tan et al., 2010; De Souza et al., 2007; Pan et al., 2010; Moreno-
Navarrete et al., 2010).  All patients received synthetic disease modifying agents.  Of 
the participants, 57.3 % were hypertensive and 40.3 % had carotid plaque.   
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TABLE 1.  RECORDED CHARACTERISTICS IN 213 PATIENTS WITH RA.   
 
Demographic characteristics  
    Age at disease onset, yrs 43.4 (13.4) 
    Age at study time, yrs 56.9 (11.1) 
    Female sex 83.1 
    Black 48.8 
    White 51.2 
 
Lifestyle factors  
    Exercise 36.8 
    Alcohol use 21.1 
    Current smoking 7.5 
 
Anthropometry  
    Body mass index, kg/m² 27.4 (5.9) 
    Waist circumference, cm 91 (13) 
    Waist-hip ratio 0.86 (81-91) 
 
Cardiovascular agents  
    Antihypertensives 46.9 
    Statins 27.2 
    Ezetimibe 0.9 
    Oral glucose-lowering agents 8.5 
    Insulin 1.4 
 
RA characteristics  
    Disease duration, yrs 13.5 (9.5) 
    Rheumatoid factor-positive 75.5 
    Clinical Disease Activity Index  7 (2-14)  
    Erythrocyte sedimentation rate, mm/h 11 (5-26) 
    C-reactive protein, mg/l 5.3 (2.2-13) 
    Interleukin 6, pg/ml   3.6 (2.2-6.0) 
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  Leukocytes, n/nl 
 
3.8 (1.4) 
    N deformed joints 9 (9) 
    Extraarticular manifestations 7.5 
    Synthetic disease-modifying agents  
        Methotrexate 84.0 
        Chloroquine 66.7 
        Leflunomide 31.0 
        Sulfasalazine 18.3 
        Azathioprine 15.0 
        Tetracycline 12.7 
        Cyclophosphamide 3.8 
        Penicillamine 3.3 
        Number 2.4 (0.9) 
    Prednisone use 2.3 
    Tumor necrosis factor-α blockade 3.8 
CKD-EPI, ml/min/1.73 m2 97 (82-116) 
 
Conventional Metabolic Risk Factors  
  
       Hypertension 57.3 
       Systolic blood pressure, mmHg 133 (21) 
       Diastolic blood pressure, mmHg 82 (12) 
       Total cholesterol, mmol/l 4.8 (1.0) 
       HDL cholesterol, mmol/l 1.52 (1.3-1.90) 
       LDL cholesterol, mmol/l 2.7 (0.8) 
       Triglycerides, mmol/l 1.0 (0.8-1.4) 
       Cholesterol-HDL cholesterol ratio 3.2 (0.9) 
       Cholesterol-HDL cholesterol ratio>4 16.8 
       Non-HDL cholesterol, mmol/l 3.8 (1.0) 
       Diabetes 11.7 
       Glucose, mmol/l 4.7 (4.4-5.2) 
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 Adipokines 
       Leptin, ng/ml 10.5 (5.5-18.4) 
       Chemerin, ng/ml 114 (35) 
       Total adiponectin, µg/ml 7.3 (4.8-12.3) 
       High molecular adiponectin, µg/ml 3.4 (1.8-5.9) 
       Resistin, ng/ml 37.4 (22.9-56.8) 
       Retinol binding protein 4, ng/ml 37.6 (20.4) 
       Omentin-1, ng/ml 9.0 (5.5-18.4) 
 
Endothelial activation molecules  
     E-selectin, ng/ml 38.5 (18.3) 
     VCAM-1, ng/ml 834 (674-1037) 
     ICAM-1, ng/ml 275 (206-353) 
     MCP-1, pg/ml 421 (261-680) 
    Angiopoietin 2, pg/ml 2.57 (2.08-3.36) 
    ADMA, µmol/l 0.63 (0.51-0.80) 
 
Plaque vulnerability  
    MMP-2, ng/ml 1,430 (624-2,435) 
    MMP-3,  pg/ml 10.2 (3.5-22.5) 
    MMP-9,  ng/ml 4,606 (3,446-6,570) 
 
Atherosclerosis  
    Intima-media thickness, mm 0.709 (0.112) 
    Plaque 40.3 
 
Dichotomous variables are expressed as proportions or percentages and continuous 
characteristics as mean ± SD or median (interquartile range).  RA: rheumatoid 
arthritis; N: number of CKD-EPI: Chronic Kidney Disease Epidemiology 
Collaboration; HDL: high-density lipoprotein; LDL: low-density lipoprotein; VCAM-1: 
vascular adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1; MCP-1: 
monocyte chemoattractant protein 1; ADMA: asymmetric dimethylarginine; MMP: 
matrix metalloproteinase. 
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Associations of baseline characteristics with omentin concentrations.   
Table 2 gives the associations of baseline characteristics with omentin 
concentrations at p<0.15, which were included in subsequent analysis as potential 
confounders.  The CKD-EPI was significantly related to omentin levels.                                                                                                                                                                                              
Independent relationships of omentin concentrations with metabolic risk factors.  
Omentin concentrations were not related to any of the conventional metabolic risk 
factors or adipokine levels (data not shown). 
Independent associations of omentin concentrations with endothelial activation 
molecule concentrations, atherosclerosis and matrix metalloproteinase levels.   
As shown in Table 3, omentin levels were inversely associated with those of matrix 
metalloproteinase-3 in both univariate (ß (SE) = -0.373 (0.122), p=0.003) and 
multivariate (ß (SE) = -0.364 (0.113), p=0.002) analysis.  In a separate model in 
which CRP concentrations (disease activity) and the deformity joint count (disease 
severity) were additionally adjusted for, omentin levels remained strongly related to 
those of matrix metalloproteinase-3 (ß (SE) = -0.378 (0.118), p=0.002).  Also, 
additional adjustment for the Framingham score (overall conventional CVD risk 
burden) or waist circumference and BMI (adiposity) did not alter the respective 
finding (ß (SE) = -0.362 (0.116), p=0.002 and ß (SE) = -0.334 (0.112), p=0.003, 
respectively).  Omentin concentrations were not related to those of endothelial 
activation molecules and cIMT and plaque presence.   
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TABLE 2.  ASSOCIATIONS OF BASELINE CHARACTERISTICS WITH OMENTIN 
CONCENTRATIONS AT P < 0.15. 
   Characteristics ß (SE) p 
Demographic characteristics 
      Age at time of the study  0.000 (0.002) 0.8 
    Age at disease onset -0.002 (0.002) 0.2 
    Female sex -0.032 (0.060) 0.6 
    Black 0.035 (0.045) 0.4 
Lifestyle factors 
      Alcohol use  0.096 (0.060) 0.1 
    Smoking 0.156 (0.083) 0.06 
Cardiovascular agents 
      Antihypertensives -0.075 (0.046) 0.1 
RA characteristics 
      CDAI* -0.081 (0.048) 0.09 
    Synthetic disease-modifying agents 
          Methotrexate 0.107 (0.061) 0.08 
        Azathioprine -0.116 (-0.061) 0.06 
    Tumor necrosis factor-α blockade 0.172 (0.117) 0.1 
Glomerular filtration rate (CKD-EPI) -0.003 (0.001) 0.04 
 
ß: regression coefficients; SE:  standard error; VCAM-1: vascular adhesion molecule 
1; CDAI: Clinical Disease Activity Index; CKD-EPI: Chronic Kidney Disease 
Epidemiology Collaboration; *logarithmically transformed; significant associations 
(values) are shown in bold. 
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TABLE 3. RELATIONSHIPS OF OMENTIN CONCENTRATIONS WITH 
ENDOTHELIAL ACTIVATION, MATRIX METALLOPROTEINASES AND 
ATHEROSCLEROSIS. 
  Univariate Multivariate 
Characteristics ß (SE) p ß (SE) p 
EA molecules     
    E-selectin -5.530(4.186) 0.2 -5.932(4.509) 0.2 
    VCAM-1* -0.016(0.034) 0.6 -0.027(0.037) 0.5 
    ICAM-1* -0.004(0.040) 0.9 0.007(0.041) 0.9 
    MCP-1 0.049(0.064) 0.4 0.084(0.068) 0.2 
    Angiopoietin 2* 0.052(0.044) 0.2 -0.058(0.045) 0.2 
    ADMA 0.039 (0.036) 0.3 0.047(0.038) 0.2 
Plaque vulnerability markers     
    MMP-2* 0.081 (0.108) 0.5 0.024(0.113) 0.8 
    MMP-3* -0.373 (0.122) 0.003 -0.364(0.113) 0.002 
    MMP-9* 0.068 (0.054) 0.2 0.083(0.056) 0.2 
Atherosclerosis     
    Intima-media thickness -0.150 (0.024) 0.5 -0.008(0.024) 0.7 
 OR(95% CI) p OR(95% CI) p 
    Plaque 1.26(0.52-3.04) 0.6 1.14(0.41-3.18) 0.3 
 
Associations were assessed in age at disease onset, race, gender, alcohol use, 
smoking, glomerular filtration rate (CKD-EPI), CDAI, methotrexate and azathioprine 
use and tumor necrosis factor-α blockade adjusted models.                                                                                                                                                                     
ß: regression coefficients; SE:  standard error; EA: endothelial activation; VCAM-1: 
vascular adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1; MCP-1: 
monocyte chemoattractant protein 1; ADMA: asymmetric dimethylarginine; MMP: 
Matrix metalloproteinase; *logarithmically transformed; significant associations 
(values) are shown in bold. 
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Impact of patient characteristics on omentin concentration - subclinical CVD 
relations.  
The potential impact of patient characteristics (see data analysis) on omentin 
concentration-endothelial activation, -atherosclerosis and -plaque vulnerability 
marker relations, were systematically explored.  Where significant interactions were 
noted, subsequent analysis in patients with and without the characteristics of interest 
was performed. 
Table 4 shows that amongst patient characteristics, CDAI, erythrocyte sedimentation 
rate (ESR), deformed joint count, generalized and abdominal adiposity and 
population origin each impacted on the omentin concentration-MMP 3 level relations.  
As also given in Table 4, this translated into consistent disparities in omentin 
concentration-MMP-3 relations amongst the respective subgroups in stratified 
analysis.  Thus, omentin levels were related to those of MMP-3 in patients without 
moderate or high disease activity (CDAI > 10) and a large ESR or deformed joint 
count.  Additionally, omentin concentrations were associated with those of MMP-3 in 
patients without but not with generalized or abdominal obesity and in white but not 
black African patients with RA.  CRP levels did not significantly impact the omentin-
MMP-3 concentration relation (interaction p = 0.1).  Nevertheless, omentin 
concentrations further related to those of MMP-3 in the 104 patients with a CRP level 
of < 5.3 mg/l (median value in all patients) but not in the 103 with a CRP 
concentration of > 5.3 mg/l (β (SE) = -0.459 (0.147), p = 0.002 and β (SE) = -0.309 
(0.198), p = 0.1, respectively).    
The CDAI impacted on the omentin concentration-cIMT relation (interaction p = 
0.02). However, as applied to the analysis amongst all patients, omentin 
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concentrations remained unrelated to cIMT in patients with (β (SE) = -0.034 (0.032), 
p=0.3) and without (β (SE) = 0.011 (0.038), p=0.8) a CDAI value of > 10.  
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TABLE 4. INDEPENDENT RELATIONSHIPS OF OMENTIN CONCENTRATIONS 
WITH MMP-3 IN SUBGROUPS 
  MMP-3  Interactions 
Subgroups Number ß (SE) p P 
Population            
   White 109 -0.450 (0.153) 0.0004  
   Black 104 -0.099 (0.195) 0.6 0.009 
BMI >29.9 kg/m2      
   No 144 -0.355 (0.124) 0.005  
   Yes 64 -0.540 (0.334) 0.1 0.02 
   Missing 5    
MetS waist     
   No 114 -0.454 (0.142) 0.002  
   Yes 96 -0.080 (0.217) 0.7 0.02 
   Missing 3    
CDAI >10     
   No 127 -0.411 (0.139) 0.004  
   Yes 85 -0.286 (0.202) 0.2 0.04 
   Missing 1    
ESR >11 mm/hr     
   No 105 -0.534 (0.161) 0.001  
   Yes 102 -0.212 (0.168) 0.2 0.04 
   Missing 6    
N Deformed joints >7     
   No 111 -0.554 (0.165) 0.001  
   Yes 101 -0.110 (0.173) 0.5 0.007 
   Missing 1    
 
Associations were assessed in age at disease onset, race, gender, alcohol use, 
smoking, compromised glomerular filtration rate (CKD-EPI), CDAI and methotrexate 
and azathioprine use and tumor necrosis factor-α blockade adjusted models.                                                                                                                                                           
MMP: matrix metalloproteinase; ß: regression coefficients; SE:  standard error; BMI:  
body mass index; MetS:  metabolic syndrome; CDAI: Clinical Disease Activity Index; 
32 
 
ESR: erythrocyte sedimentation rate; *logarithmically transformed; significant 
associations(values) are shown in bold. 
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The present study documents that omentin concentrations are strongly and inversely 
associated with those of MMP-3 in patients with RA.  MMP-3 expression is altered in 
obesity (Traurig et al., 2006) and its circulating concentrations can represent disease 
activity (Keyszer et al., 1999) and joint damage (Yamanaka et al., 2000) in RA.  The 
omentin-MMP-3 concentration relation in the present investigation was independent 
of adiposity measures and the CDAI and deformity joint count as well as a large 
number of other potential confounders.   
Matrix metalloproteinases are endopeptidases that mediate remodeling of the 
extracellular matrix (Back et al., 2010).  MMP-3 is highly expressed in the shoulders 
(of plaques) and regions of foam cell accumulation of atherosclerotic plaques (Galis 
et al., 1994).  Enhanced MMP-3 expression colocalizes with casein lysis in 
atherosclerotic lesions, which supports its increased activity (Galis et al., 1994).  
Circulating MMP-3 concentrations are increased in patients with atherosclerosis 
(Beaudeux et al., 2003).  Reported evidence indicates that MMP-3 may particularly 
contribute to the progression of atherosclerosis (Samnegard et al., 2006).  Against 
this background, our present findings indicate that although omentin concentrations 
are not related to prevalent atherosclerosis in RA as in the non-RA population 
(Shibata et al., 2011; Liu & Wang et al., 2011; Kadoglou et al., 2014), this molecule 
may nevertheless contribute to its acceleration, which is well recognized in this 
disease (Dessein et al., 2007; Solomon et al., 2010; Nurmohamed et al., 2010; 
Peters et al., 2010).  Future longitudinal investigations are needed to address this 
possibility.    
MMP-3 levels also predict incident cardiovascular event rates amongst patients with 
stable coronary artery disease (Wu et al., 2005).  MMP-3 is overexpressed in 
coronary atherosclerotic lesions that exhibit positive arterial remodelling, which is 
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associated with unstable clinical presentation (Schoenhagen et al., 2002).  Although 
reduced circulating MMP-3 concentrations were recently reported in patients with 
acute coronary syndrome (ACS) (Samnegard et al., 2006), circulating MMP-3 levels 
in ACS patients may not represent local concentrations at the site of plaque rupture.  
Thus, in blood withdrawn from the coronary sinus but not aorta, MMP-3 
concentrations were actually larger in ACS patients compared to those with stable 
coronary disease and controls (Inoue et al., 2003).  Plaque vulnerability is increased 
and related to disease activity in RA (Aubry et al., 2007; Stamatelopoulos et al, 
2007).  These reported findings together with our current results suggest that 
omentin can enhance plaque vulnerability to rupture in RA as reported in non-RA 
subjects (Kadoglou et al., 2014).     
Importantly in the context of RA, we found that disease activity and severity and the 
ESR consistently modified the omentin-MMP-3 relation in RA.  Indeed, we have 
previously reported that similar to in non-RA subjects, the potential impact of 
adipokines on CVD risk is frequently influenced by disease characteristics in RA 
(Dessein et al., 2013a; Dessein et al., 2013c; Dessein et al., 2013e ;Dessein et al., 
2014a; Dessein et al., 2014b; Dessein et al., 2014c; Dessein et al., 2014d; Dessein 
et al., 2014e). Our present results show that the potential beneficial effects of 
omentin on CVD risk are lost in patients with moderate and marked RA activity, a 
high ESR value and extensive joint damage.  An abrogated impact of omentin may 
therefore contribute to the recognized increased CVD risk associated with severe RA 
(Dessein et al., 2007; Solomon et al., 2010; Nurmohamed et al., 2010; Peters et al., 
2010).  This has implications in CVD risk management through adequate RA activity 
and inflammation control. 
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The impact of excess adiposity on CVD risk in RA is controversial at present (Kitas & 
Gabriel, 2011; Stavropoulos et al., 2011).  Nevertheless, in our setting, excess 
adiposity increases cardiovascular risk in patients with RA (Solomon et al., 2011).  
Congruently, our current analysis disclosed that the potentially protective effects of 
omentin against CVD are also lost in RA patients with generalized or abdominal 
obesity.  Whether management of obesity can reduce CVD risk by altering omentin 
effects in RA merits further investigation.   
Population origin was not associated with altered omentin concentrations.  However, 
contrary to our findings in white African participants with RA, black patients did not 
experience an omentin concentration related decrease in MMP-3.  Disparities in the 
associations of polymorphisms in adipokine related genes with subclinical CVD 
amongst black and white participants were previously documented in the multi-ethnic 
study of atherosclerosis (Wassel et al., 2011).  These findings and our current results 
reinforce the need for population specific CVD risk stratification (Solomon et al., 
2014).   
The omentin-MMP-3 concentration relationship was also independent of the 
Framingham score, which predicts severe or high risk atherosclerosis to a clinically 
useful extent in RA (Dessein et al., 2016).  Consideration of omentin concentrations 
may enhance CVD risk stratification in RA. 
In the present study, the estimated glomerular filtration rate comprised the only 
baseline characteristic that was significantly and inversely associated with omentin 
concentrations.  High omentin concentrations were previously documented in non-
RA patients with renal impairment (Sengul et al., 2013).  Notably, the associations of 
omentin concentrations with conventional metabolic risk and levels of other 
37 
 
adipokines that were disclosed in non-RA subjects (Pan et al., 2010; Moreno-
Navarrete et al., 2010; Saremi et al., 2010; Shibata et al., 2012) were not reproduced 
in our patients with RA.  This argues against the indiscriminate extrapolation of 
reported findings on the role of omentin in reduced metabolic CVD risk in the non-RA 
population, to patients with RA.   
We recently reported that adiponectin, leptin, resistin, retinol binding protein-4 and 
chemerin levels were each independently related to endothelial activation and 
atherosclerosis extent in RA (Dessein et al., 2013a; Dessein et al., 2013c; Dessein 
et al., 2013e ;Dessein et al., 2014a; Dessein et al., 2014b; Dessein et al., 2014c; 
Dessein et al., 2014d; Dessein et al., 2014e). Interestingly, these findings contrast to 
our current results obtained in all patients as well as in various subgroups.  The 
potential impact of adipokines other than omentin on MMP concentrations has, to our 
knowledge, not been reported to date. 
This investigation comprises comprehensively assessed RA patients.  Apart from 
previously mentioned limitations, our coss-sectional study design precludes drawing 
inferences on the direction of causality.  Although omentin is overall considered to 
reduce CVD risk (Shaffler et al., 2005; Yang et al., 2006; Tan et al., 2010; De Souza 
et al., 2007; Pan et al., 2010; Moreno-Navarrete et al., 2010; Saremi et al., 2010; 
Shibata et al., 2012; Yamawaki et al., 2010; Zhong et al., 2012; Yoo et al., 2011; 
Shibata et al., 2011a; Liu et al., 2011; Kadoglou et al., 2014; Shang et al., 2011; 
Zhong et al., 2011; Shibata et al., 2011b; Greulich et al., 2013; Namuri et al., 2014), 
in a recent prospective study in 295 patients with established or suspected stable 
coronary artery disease, omentin concentrations were directly related to incident 
cardiovascular events (Saely et al., 2016).  This may have represented a paradoxical 
and compensatory alteration in omentin production because of prevalent CVD and 
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aimed at reducing this risk.  Indeed, similar findings on the potential effects of 
adiponectin on CVD risk were previously reported in both RA and non-RA subjects 
(Dessein et al., 2013a; Dessein et al. 2013e; Sattar & Nelson, 2008).   
In conclusion, omentin concentrations do not represent endothelial activation and 
atherosclerosis extent in RA. However, omentin concentrations were inversely 
associated with those of MMP-3, a surrogate marker of plaque vulnerability to 
rupture, in white but not black Africans with RA.  This inverse relationship was also 
absent RA patients with moderate or severe RA activity and large ESR values and 
joint deformity counts.  A loss of beneficial effects of omentin on plaque instability 
may contribute to the link between severe disease and increased cardiovascular risk 
in RA.  The role of omentin in plaque vulnerability and CVD risk stratification 
amongst patients with RA merits future longitudinal investigation.                                                                                                                                                   
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